Clozapine for acute and maintenance treatment of psychosis in Parkinson's disease.
Identifieur interne : 000299 ( PubMed/Corpus ); précédent : 000298; suivant : 000300Clozapine for acute and maintenance treatment of psychosis in Parkinson's disease.
Auteurs : R Chacko ; R Hurley ; R Harper ; J. Jankovic ; F. CardosoSource :
- The Journal of neuropsychiatry and clinical neurosciences [ 0895-0172 ] ; 1995.
English descriptors
- KwdEn :
- Aged, Antipsychotic Agents (adverse effects), Antipsychotic Agents (therapeutic use), Clozapine (adverse effects), Clozapine (therapeutic use), Female, Follow-Up Studies, Humans, Male, Middle Aged, Neurocognitive Disorders (drug therapy), Neurocognitive Disorders (psychology), Neuropsychological Tests, Parkinson Disease (drug therapy), Parkinson Disease (psychology), Prospective Studies, Social Behavior.
- MESH :
- chemical , adverse effects : Antipsychotic Agents, Clozapine.
- chemical , therapeutic use : Antipsychotic Agents, Clozapine.
- drug therapy : Neurocognitive Disorders, Parkinson Disease.
- psychology : Neurocognitive Disorders, Parkinson Disease.
- Aged, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neuropsychological Tests, Prospective Studies, Social Behavior.
Abstract
In a prospective, open-label study, 12 patients manifesting psychosis associated with Parkinson's disease were treated with clozapine. Cognitive functioning and type of psychotic symptoms were measured prior to treatment, and changes in psychiatric and behavioral symptoms were studied by using the Behave-AD Scale. Significant resolution in psychotic symptoms was found and improvement in global behavioral status observed in all cases, with 10 patients maintaining improvement at follow-up. Careful initiation and titration of the drug resulted in few side effects, and dementia was not found to be a contraindication to such treatment.
DOI: 10.1176/jnp.7.4.471
PubMed: 8555750
Links to Exploration step
pubmed:8555750Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clozapine for acute and maintenance treatment of psychosis in Parkinson's disease.</title><author><name sortKey="Chacko, R C" sort="Chacko, R C" uniqKey="Chacko R" first="R" last="Chacko">R Chacko</name><affiliation><nlm:affiliation>Department of Psychiatry/Behavioral Sciences, Baylor College of Medicine, Houston, Texas, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Hurley, R A" sort="Hurley, R A" uniqKey="Hurley R" first="R" last="Hurley">R Hurley</name></author><author><name sortKey="Harper, R G" sort="Harper, R G" uniqKey="Harper R" first="R" last="Harper">R Harper</name></author><author><name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J" last="Jankovic">J. Jankovic</name></author><author><name sortKey="Cardoso, F" sort="Cardoso, F" uniqKey="Cardoso F" first="F" last="Cardoso">F. Cardoso</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1995">1995</date><idno type="RBID">pubmed:8555750</idno><idno type="pmid">8555750</idno><idno type="doi">10.1176/jnp.7.4.471</idno><idno type="wicri:Area/PubMed/Corpus">000299</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Clozapine for acute and maintenance treatment of psychosis in Parkinson's disease.</title><author><name sortKey="Chacko, R C" sort="Chacko, R C" uniqKey="Chacko R" first="R" last="Chacko">R Chacko</name><affiliation><nlm:affiliation>Department of Psychiatry/Behavioral Sciences, Baylor College of Medicine, Houston, Texas, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Hurley, R A" sort="Hurley, R A" uniqKey="Hurley R" first="R" last="Hurley">R Hurley</name></author><author><name sortKey="Harper, R G" sort="Harper, R G" uniqKey="Harper R" first="R" last="Harper">R Harper</name></author><author><name sortKey="Jankovic, J" sort="Jankovic, J" uniqKey="Jankovic J" first="J" last="Jankovic">J. Jankovic</name></author><author><name sortKey="Cardoso, F" sort="Cardoso, F" uniqKey="Cardoso F" first="F" last="Cardoso">F. Cardoso</name></author></analytic><series><title level="j">The Journal of neuropsychiatry and clinical neurosciences</title><idno type="ISSN">0895-0172</idno><imprint><date when="1995" type="published">1995</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antipsychotic Agents (adverse effects)</term><term>Antipsychotic Agents (therapeutic use)</term><term>Clozapine (adverse effects)</term><term>Clozapine (therapeutic use)</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neurocognitive Disorders (drug therapy)</term><term>Neurocognitive Disorders (psychology)</term><term>Neuropsychological Tests</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (psychology)</term><term>Prospective Studies</term><term>Social Behavior</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antipsychotic Agents</term><term>Clozapine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antipsychotic Agents</term><term>Clozapine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Neurocognitive Disorders</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Neurocognitive Disorders</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neuropsychological Tests</term><term>Prospective Studies</term><term>Social Behavior</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In a prospective, open-label study, 12 patients manifesting psychosis associated with Parkinson's disease were treated with clozapine. Cognitive functioning and type of psychotic symptoms were measured prior to treatment, and changes in psychiatric and behavioral symptoms were studied by using the Behave-AD Scale. Significant resolution in psychotic symptoms was found and improvement in global behavioral status observed in all cases, with 10 patients maintaining improvement at follow-up. Careful initiation and titration of the drug resulted in few side effects, and dementia was not found to be a contraindication to such treatment.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">8555750</PMID><DateCreated><Year>1996</Year><Month>02</Month><Day>27</Day></DateCreated><DateCompleted><Year>1996</Year><Month>02</Month><Day>27</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0895-0172</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>4</Issue><PubDate><Year>1995</Year><Season>Fall</Season></PubDate></JournalIssue><Title>The Journal of neuropsychiatry and clinical neurosciences</Title><ISOAbbreviation>J Neuropsychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Clozapine for acute and maintenance treatment of psychosis in Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>471-5</MedlinePgn></Pagination><Abstract><AbstractText>In a prospective, open-label study, 12 patients manifesting psychosis associated with Parkinson's disease were treated with clozapine. Cognitive functioning and type of psychotic symptoms were measured prior to treatment, and changes in psychiatric and behavioral symptoms were studied by using the Behave-AD Scale. Significant resolution in psychotic symptoms was found and improvement in global behavioral status observed in all cases, with 10 patients maintaining improvement at follow-up. Careful initiation and titration of the drug resulted in few side effects, and dementia was not found to be a contraindication to such treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chacko</LastName><ForeName>R C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Psychiatry/Behavioral Sciences, Baylor College of Medicine, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hurley</LastName><ForeName>R A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Harper</LastName><ForeName>R G</ForeName><Initials>RG</Initials></Author><Author ValidYN="Y"><LastName>Jankovic</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Cardoso</LastName><ForeName>F</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>J Neuropsychiatry Clin Neurosci</MedlineTA><NlmUniqueID>8911344</NlmUniqueID><ISSNLinking>0895-0172</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>J60AR2IKIC</RegistryNumber><NameOfSubstance UI="D003024">Clozapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014150">Antipsychotic Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003024">Clozapine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019965">Neurocognitive Disorders</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009483">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000523">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012919">Social Behavior</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1995</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1995</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1995</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8555750</ArticleId><ArticleId IdType="doi">10.1176/jnp.7.4.471</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/JankovicV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000299 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000299 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= JankovicV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:8555750
|texte= Clozapine for acute and maintenance treatment of psychosis in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:8555750" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a JankovicV1
| This area was generated with Dilib version V0.6.19. |  |